Rational redesign of antigen binding domain improves in vivo efficacy of CD22-CAR T cells
Kole DeGolier, Zachary H. Walsh, Lillie Leach…·Terry J. Fry
This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.